2-bromo-1-(7-methoxybenzofuran-2-yl)ethanone | 1210038-76-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: 2-bromo-1-(7-methoxybenzofuran-2-yl)ethanone
• 英文别名: 2-Bromo-1-(7-methoxy-1-benzofuran-2-yl)ethan-1-one；2-bromo-1-(7-methoxy-1-benzofuran-2-yl)ethanone
• CAS: 1210038-76-8
• 化学式: C₁₁H₉BrO₃
• 分子量: 269.095
• InChiKey: BMEWKFJUOJVBPO-UHFFFAOYSA-N

物化性质

• 沸点：
  347.0±27.0 °C(Predicted)
• 密度：
  1.537±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  39.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-bromo-1-(7-methoxybenzofuran-2-yl)ethanone 在 间氯过氧苯甲酸 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 0.08h， 生成 6-(7-methoxybenzofuran-2-yl)-2-(methylsulfonyl)imidazo[2,1-b][1,3,4]thiadiazole
  参考文献：
  名称：

  发现具有体内抗血栓功效的强蛋白酶激活的受体4拮抗剂。

  摘要：

  为了确定新型抗血栓形成剂，我们通过在猴子血栓形成模型中开发和评估工具化合物UDM-001651，研究了蛋白酶激活的受体4（PAR4）拮抗作用。从高通量筛选开始，我们确定了基于咪唑并噻二唑的PAR4拮抗剂化学型。详细的结构-活性关系研究能够优化有效，选择性和口服生物利用的PAR4拮抗剂UDM-001651。UDM-001651在猴子血栓形成模型中进行了评估，显示具有强大的抗血栓形成功效，并且不会延长肾脏的出血时间。优异的疗效和安全性相结合，强有力地验证了PAR4拮抗作用是一种有前途的抗血栓形成机制。

  DOI：

  10.1021/acs.jmedchem.9b00186
• 作为产物：
  描述：

  2-乙酰基-7-甲氧基苯并呋喃 在 N-溴代丁二酰亚胺(NBS) 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 为溶剂， 反应 1.5h， 生成 2-bromo-1-(7-methoxybenzofuran-2-yl)ethanone
  参考文献：
  名称：

  发现具有体内抗血栓功效的强蛋白酶激活的受体4拮抗剂。

  摘要：

  为了确定新型抗血栓形成剂，我们通过在猴子血栓形成模型中开发和评估工具化合物UDM-001651，研究了蛋白酶激活的受体4（PAR4）拮抗作用。从高通量筛选开始，我们确定了基于咪唑并噻二唑的PAR4拮抗剂化学型。详细的结构-活性关系研究能够优化有效，选择性和口服生物利用的PAR4拮抗剂UDM-001651。UDM-001651在猴子血栓形成模型中进行了评估，显示具有强大的抗血栓形成功效，并且不会延长肾脏的出血时间。优异的疗效和安全性相结合，强有力地验证了PAR4拮抗作用是一种有前途的抗血栓形成机制。

  DOI：

  10.1021/acs.jmedchem.9b00186

文献信息

• Synthesis and bioactivity of novel C2-glycosyl benzofuranylthiazoles derivatives as acetylcholinesterase inhibitors
  作者：Lei Wang、Yu-Ran Wu、Shu-Ting Ren、Long Yin、You-Xian Wang、Shu-Hao Liu、Wei-Wei Liu、Da-Hua Shi、Zhi-Ling Cao、Hui-Min Sun

  DOI：10.1177/1747519819856973

  日期：2019.7

  A new series of C2-glycosyl benzofuranylthiazole derivatives was synthesised by the further cyclization of glycosyl thiourea and 2-(bromoacetyl)-benzofuran via Hantzsch’s method. The corresponding 2-(bromoacetyl)-benzofuran derivatives were obtained by the reaction from various salicylaldehydes, and the glycosyl thiourea was prepared through a series of steps from D-Glucosamine. The acetylcholinesterase-inhibitory

  通过Hantzsch法进一步环化糖基硫脲和2-(溴乙酰基)-苯并呋喃，合成了一系列新的C2-糖基苯并呋喃基噻唑衍生物。由各种水杨醛反应得到相应的2-(溴乙酰基)-苯并呋喃衍生物，由D-氨基葡萄糖通过一系列步骤制备糖基硫脲。产品的乙酰胆碱酯酶抑制活性通过 Ellman 方法测试。随后评估了最具活性的化合物的 50% 抑制浓度值。N-(1,3,4,6-四-O-苄基-2-脱氧-β-D-吡喃葡萄糖基)-4-(5-甲氧基-苯并呋喃-2-基)-1,3-噻唑-2-胺具有最佳的乙酰胆碱酯酶抑制活性，50% 抑制浓度为 2.03 ± 0.26 μM。
• Pyrrole derivative having, as substituents, ureido group, aminocarbonly group and bicyclic group which may have substituent
  申请人：Santen Pharmaceutical Co., Ltd.

  公开号：US08088817B2

  公开（公告）日：2012-01-03

  A compound represented by the following formula (1) or a salt thereof: The compound has an inhibitory activity on the production of interleukin-6, and is therefore useful as a therapeutic agent for a disease associated with interleukin-6, ocular inflammatory diseases and the like. In the formula, R1 represents a halogen atom, a hydrogen atom, a lower alkyl group which may have a substituent, a formyl group, or a lower alkylcarbonyl group which may have a substituent, R2 represents a bicyclic hydrocarbon group which may have a substituent or a bicyclic heterocyclic group which may have a substituent, R3 represents a hydrogen atom, a lower alkyl group which may have a substituent, an aryl group which may have a substituent, or an acyl group.

  以下式（1）所表示的化合物或其盐： 该化合物具有抑制白细胞介素-6的产生活性，因此可用作治疗与白细胞介素-6、眼部炎症等相关的疾病的治疗剂。在该式中，R1代表卤素原子、氢原子、可能具有取代基的低碳基、甲酰基或可能具有取代基的低碳基酰基，R2代表可能具有取代基的双环烃基或双环杂环基，R3代表氢原子、可能具有取代基的低碳基、可能具有取代基的芳基或酰基。
• NOVEL PYRROLE DERIVATIVE HAVING, AS SUBSTITUENTS, UREIDO GROUP, AMINOCARBONLY GROUP AND BICYCLIC GROUP WHICH MAY HAVE SUBSTITUENT
  申请人：Kawashima Kenji

  公开号：US20110136794A1

  公开（公告）日：2011-06-09

  A compound represented by the following formula (1) or a salt thereof: The compound has an inhibitory activity on the production of interleukin-6, and is therefore useful as a preventive and/or therapeutic agent for a disease associated with interleukin-6, ocular inflammatory diseases and the like. In the formula, R 1 represents a halogen atom, a hydrogen atom, a lower alkyl group which may have a substituent, a formyl group, or a lower alkylcarbonyl group which may have a substituent, R 2 represents a bicyclic hydrocarbon group which may have a substituent or a bicyclic heterocyclic group which may have a substituent, R 3 represents a hydrogen atom, a lower alkyl group which may have a substituent, an aryl group which may have a substituent, or an acyl group.

  以下式子（1）所表示的化合物或其盐：该化合物具有抑制白细胞介素-6产生的活性，因此可用作预防和/或治疗与白细胞介素-6有关的疾病，如眼部炎症性疾病等的药物。在该式中，R1表示卤素原子、氢原子、可能具有取代基的较低烷基、甲酰基或可能具有取代基的较低烷基羰基基团，R2表示可能具有取代基的双环烃基团或双环杂环基团，R3表示氢原子、可能具有取代基的较低烷基、可能具有取代基的芳基或酰基基团。
• IMIDAZOTHIADIAZOLE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20150133446A1

  公开（公告）日：2015-05-14

  The present invention provides imidazothiadiazole compounds of Formula (I) wherein A, B, D, R x , R 1 , R 2 , R 3 , X 1 , X 2 and s are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments.

  本发明提供了式（I）的咪唑噻二唑化合物，其中A、B、D、Rx、R1、R2、R3、X1、X2和s如本文所定义，或其立体异构体、互变异构体、药学上可接受的盐或溶剂形式，其中所有变量均如本文所定义。这些化合物是血小板聚集抑制剂，因此可用作药物。
• NOVEL PYRROLE DERIVATIVE HAVING, AS SUBSTITUENTS, UREIDE GROUP, AMINOCARBONYL GROUP AND BICYCLIC GROUP WHICH MAY HAVE SUBSTITUENT
  申请人：Santen Pharmaceutical Co., Ltd

  公开号：EP2319831A1

  公开（公告）日：2011-05-11

  Disclose is a novel pyrrole derivative having, as substituents, a ureido group, an aminocarbonyl group and a bicyclic group which may have a substituent, or a salt of the derivative. A compound represented by general formula (1) or a salt thereof has an inhibitory activity on the production of interleukin-6, and is therefore useful as a preventive and/or therapeutic agent for a disease associated with interleukin-6, ocular inflammatory diseases and the like. In the formula, R1 represents a halogen atom, a hydrogen atom, a lower alkyl group which may have a substituent, a formyl group, or a lower alkylcarbonyl group which may have a substituent, R2 represents a bicyclic hydrocarbon group which may have a substituent or a bicyclic heterocyclic group which may have a substituent, R3 represents a hydrogen atom, a lower alkyl group which may have a substituent, an aryl group which may have a substituent, or an acyl group.

  本发明公开了一种新型吡咯衍生物，该衍生物具有脲基、氨基羰基和可具有取代基的双环基，或该衍生物的盐。通式（1）所代表的化合物或其盐具有抑制白细胞介素-6 生成的活性，因此可作为白细胞介素-6 相关疾病、眼部炎症等的预防和/或治疗剂。式中，R1 代表卤素原子、氢原子、可能具有取代基的低级烷基、甲酰基或可能具有取代基的低级烷基羰基，R2 代表可能具有取代基的双环烃基或可能具有取代基的双环杂环基，R3 代表氢原子、可能具有取代基的低级烷基、可能具有取代基的芳基或酰基。